Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | GCK | P35557 | 10/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL564574 | 0.90 | SYK (0.38) | SYKGCKXDH | |
| SCHEMBL1076075 | 0.89 | KMT2A (0.39) | KMT2AGCKKDM4EALDH1A1HPGD | |
| SCHEMBL564458 | 0.88 | RAB9A (0.44) | KMT2AGCKKDM4EALDH1A1HPGD | |
| SCHEMBL1075201 | 0.87 | KDM4E (0.44) | KMT2AGCKKDM4EALDH1A1HPGD | |
| SCHEMBL563982 | 0.87 | KMT2A (0.38) | KMT2AGCKKDM4EALDH1A1HPGD | |
| SCHEMBL563627 | 0.87 | GCK (0.33) | GCKXDHCYP1A2CYP2C9 | |
| SCHEMBL1074706 | 0.85 | GCK (0.38) | KMT2AGCKKDM4EALDH1A1HPGD | |
| SCHEMBL564651 | 0.83 | KMT2A (0.60) | KMT2AKDM4EALDH1A1HPGDLMNA | |
| SCHEMBL12734229 | 0.81 | XDH (0.41) | KMT2AGCKKDM4EALDH1A1HPGD | |
| SCHEMBL1076738 | 0.81 | GCK (0.37) | KMT2AGCKKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557805-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-02-09 | — | — | US | disclosed |
| EP-2371826-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | GPR119, GCKR, SLC5A1 | KMT2A 1470/4885SYK 1694/4885GCK 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.